Product Name:

Rhinogen ^® DM1, Maytansinoid DM1, N2'- deacetyl -N2'-(3-mercapto-1- oxopropyl)- maytansine, N2' - Deacetyl-N2 ' -(3-mercapto-1- oxopropyl )- maytansine .

Chemical Information:

Molecular formula : C₃₅H₄₈ClN₃O₁S 

Molecular weight: 738.29

CAS No.: No.139504-50-0

background:

DM1 is a derivative of Maytansine , which inhibits tubulin aggregation by binding to the periwinkle site. DM1 is coupled to a targeted antibody through a linker to prepare a targeted ADC anti-tumor drug to enhance its efficacy.

Rhinogen ^® DM1 is a white crystalline powder, slightly soluble in methanol or ethanol, slightly soluble in chloroform, and almost insoluble in water. Specific rotation α _D ²⁵ (CH ₃ Cl): -122.9°, melting point 196.1~201.9°C, characteristic absorption at 232nm, 253nm, 280nm, 288nm, the maximum single impurity is less than 0.1%, the residual solvent complies with the national pharmacopoeia, and the Rhinogen ^® DM1 content is more than 98%.

Rhinozyme has developed a production process with independent intellectual property rights based on its fermentation technology platform to obtain high-quality Rhinogen ^® Ansamitocin P-3. Using Rhinogen ® Ansamitocin P-3 as a chemical precursor, the small molecule anti-tumor drug DM1 was synthesized on a large scale .

Rhinogen ^® DM1 Advantages:

The production of DM1 is not restricted by raw materials and the quality is more guaranteed.